Health Topics — Skin & Topical
Bladder Function and Cannabinoids: Pagano (2015) and Beyond
The bladder expresses CB1 and CB2 receptors throughout its tissue layers, and the Pagano group found CBG the most effective of five cannabinoids tested in reducing bladder contractility — what that finding means, what it doesn't, and where the research stands.
Procedural Note
Bladder conditions including overactive bladder, interstitial cystitis, and bladder dysfunction associated with neurological conditions are managed under urologist care. Established pharmacological and non-pharmacological treatments exist. This article discusses preclinical research only. Nothing here constitutes guidance on managing any bladder condition. People with bladder dysfunction should work with their urologist on treatment decisions.
The bladder is not a structure most people associate with the endocannabinoid system. It has one — CB1 and CB2 receptors are expressed in urothelial cells lining the bladder, in the detrusor smooth muscle that contracts to expel urine, and in the sensory nerve fibers that signal bladder fullness. The Pagano 2015 study found that of the cannabinoids it tested, CBG produced the strongest reduction in bladder contractility — a finding specific enough to document carefully and limited enough to require that documentation to be honest.
The Bladder's ECS Architecture
The bladder wall has three functional layers relevant to cannabinoid research. The urothelium — the innermost cell layer lining the bladder cavity — is not merely a passive barrier. Urothelial cells express CB1 and CB2 receptors, produce endocannabinoids, and release signaling molecules including ATP and acetylcholine in response to bladder filling and stretch. They participate actively in communicating bladder fullness to the sensory nervous system.
Beneath the urothelium lies the lamina propria, a connective tissue layer containing sensory nerve fibers, interstitial cells, and blood vessels. Sensory afferent neurons in the lamina propria — which carry the signal of bladder distension to the spinal cord and brain — express both CB1 and TRPV1 receptors. CB1 activation on these sensory fibers reduces their firing threshold sensitivity, effectively quieting the urgency signals that drive the sensation of needing to urinate. TRPV1 channels on the same fibers are activated by noxious stimuli and contribute to the hypersensitivity characteristic of conditions like interstitial cystitis.
The outermost functional layer is the detrusor — the smooth muscle that contracts coordinately during urination to expel urine from the bladder. Detrusor muscle cells express CB1 receptors, and CB1 activation in detrusor tissue reduces spontaneous contractile activity. This is the layer most directly relevant to the Pagano study findings.
The Pagano Study — Design and Findings
Study Design: Ex vivo study using excised mouse bladder tissue. Bladder strips — sections of detrusor muscle removed from the animal and kept alive in physiological solution — were exposed to electrical field stimulation to trigger contractile activity, then treated with cannabinoids to measure changes in contraction frequency and amplitude. This ex vivo preparation preserves the tissue architecture and neuromuscular signaling of intact bladder muscle while allowing precise control over drug concentrations and stimulation parameters.
Cannabinoids Tested: Five cannabinoids were compared: CBG, CBD, CBC, CBDV (cannabidivarin), and THCV (tetrahydrocannabivarin). All five were tested across a concentration range; effects on electrically stimulated detrusor contractions were measured at each concentration. The comparative design is the study's most useful feature — it places CBG's activity in direct context against structurally related compounds under identical conditions.
CBG Findings: CBG produced the most potent reduction in bladder contractility of the five cannabinoids tested — reducing both the frequency and amplitude of electrically stimulated detrusor contractions in a concentration-dependent manner. At the concentrations tested, CBG's effects were statistically significant and stronger than those of CBD, CBC, CBDV, and THCV in this model. CBD and CBDV also produced significant reductions, but at higher concentrations relative to CBG's effective range.
Mechanism: The study examined receptor involvement using CB1 and CB2 antagonists. CB1 blockade partially attenuated CBG's effects on detrusor contractility, suggesting CB1 contributes to the mechanism. The effects were not fully abolished by CB1 blockade alone, consistent with CBG's multi-target pharmacology and the likely involvement of additional pathways including TRPV1 and TRP channel interactions in bladder sensory tissue.
What the Study Establishes: CBG reduces detrusor muscle contractility in excised mouse bladder tissue more potently than four other cannabinoids tested under identical conditions. This is a specific, comparative, and mechanistically informative preclinical finding. It establishes biological activity in the relevant tissue, not a treatment effect in a living animal or human with a bladder condition.
From Ex Vivo Tissue to Overactive Bladder — The Translation Gap
Overactive bladder — characterized by urinary urgency, increased urination frequency, and in some cases urgency incontinence — affects tens of millions of adults. Its causes are heterogeneous: age-related changes in detrusor muscle compliance, neurological conditions that disrupt bladder-brain signaling, inflammatory changes in the urothelium, and idiopathic detrusor overactivity all contribute to varying degrees in different patients. Current treatments include anticholinergic medications (oxybutynin, tolterodine) and beta-3 agonists (mirabegron), which reduce detrusor overactivity through distinct mechanisms, as well as behavioral interventions and, for refractory cases, botulinum toxin injections or neuromodulation.
The Specific Gaps Between the Pagano Finding and Clinical Relevance
The Pagano study used excised tissue in physiological solution — not a living animal with intact bladder innervation, autonomic regulation, and circulating hormones. The detrusor contractions were electrically stimulated rather than arising from the neurological voiding reflex that drives urgency in overactive bladder. Whether CBG would reduce involuntary detrusor contractions in a living animal model of overactive bladder has not been tested.
No animal model of overactive bladder with CBG has been published, and no human data exists. The concentrations active in the ex vivo model and what oral doses in a human would produce in bladder tissue have not been studied. Interstitial cystitis — the inflammatory bladder pain condition where CB2-mediated anti-inflammatory mechanisms would be particularly relevant — has not been directly examined in cannabinoid research involving CBG specifically.
The Honest Evidence Summary
The Pagano 2015 study documents that CBG reduces detrusor smooth muscle contractility in excised bladder tissue more potently than four other cannabinoids tested under the same conditions. The finding has a plausible CB1-mediated mechanism, is specific and comparative, and represents genuine preclinical evidence of biological activity in relevant tissue. It is the most direct CBG evidence in this domain and earns its Tier 2 designation.
No animal model or human clinical data follows it. The ex vivo tissue model is several steps removed from the clinical conditions — overactive bladder, interstitial cystitis, neurogenic bladder dysfunction — where this finding would need to be relevant to matter for patients. Bladder conditions are effectively managed by urologists using established treatments. This research does not constitute an alternative to that care, and the archive does not present it as one.
References
- Pagano, E., Romano, B., Iannotti, F.A., et al. (2015). The non-psychoactive plant cannabinoid, cannabigerol, with other minor phytocannabinoids, reduces the contractility of the human detrusor muscle: A potential treatment for overactive bladder. British Journal of Pharmacology, 172(12), 3009–3022.
- Avelino, A., Cruz, C., Nagy, I., & Cruz, F. (2004). Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience, 123(4), 1005–1015.
- Bíró, T., Tóth, B.I., Haskó, G., et al. (2009). The endocannabinoid system of the skin in health and disease. Trends in Pharmacological Sciences, 30(8), 411–420.
- Gratzke, C., Streng, T., Park, A., et al. (2009). Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. Journal of Urology, 181(4), 1939–1948.
- Tyagi, P., Tyagi, V., Yoshimura, N., & Chancellor, M. (2009). Functional role of cannabinoid receptors in the lower urinary tract. Indian Journal of Urology, 25(1), 112–116.
- Walczak, J.S., Price, T.J., & Cervero, F. (2009). Role of spinal cannabinoid CB1 receptors in the control of pain and spasticity in a model of multiple sclerosis. Neuroscience, 160(2), 399–407.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.